As TP53 mutations are a hallmark of uterine serous carcinoma, while ARID1A mutations comprise roughly half of uterine endometrioid adenocarcinoma, we also observed that both Hallmark pathway and GO Biological Process GSEA results significantly correlated in a comparison between ARID1A mutant vs. TP53 mutant tumors and endometrioid vs. serous histological subtype (S6B and S6C Fig). This evidence concerns the gene ARID1A and endometrioid adenocarcinoma.